Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players√Ę‚ā¨‚ĄĘ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Bulimia Nervosa Companies

Bulimia nervosa is a serious mental health condition characterized by recurrent episodes of binge eating followed by compensatory behaviors such as vomiting, excessive exercise, or fasting. The treatment of bulimia nervosa typically involves a multidisciplinary approach, including psychotherapy, nutritional counseling, and sometimes medication. While there may not be specific companies dedicated solely to treating bulimia nervosa, various pharmaceutical companies, mental health clinics, and healthcare providers play a role in addressing this disorder. 

Bulimia Nervosa Market

 


Latest Bulimia Nervosa Companies Updates:


King's College London (UK): Launched the largest ever study on eating disorders, including bulimia nervosa, in January 2024. This research aims to unlock insights into the causes and personalize treatment approaches.


National Institute of Mental Health (NIMH): Funded research in October 2023 exploring the use of digital therapeutics, like mobile apps and AI-powered interventions, for bulimia nervosa.


Eating Recovery Center (US): Announced progress in developing a Virtual Reality (VR) therapy program specifically for bulimia nervosa, aiming to provide immersive exposure therapy and coping skills training.


National Eating Disorders Association (NEDA): Launched a campaign in September 2023 titled "Break the Cycle: Bulimia Nervosa Awareness Week," promoting early identification and access to treatment.


Beats (UK): Partnered with mental health experts in October 2023 to develop resources and support systems for individuals struggling with eating disorders, including bulimia nervosa, accessible through their streaming platform.Headspace (US): Introduced new guided meditations and mindfulness exercises specifically targeting bulimia nervosa symptoms and urges, accessible within their app.


 


List of Bulimia Nervosa Key companies in the market:



  • Allergan, Inc. (Ireland)

  • Eli Lilly and Company (US)

  • AstraZeneca (UK)

  • Bristol-Myers Squibb Company (US)

  • GlaxoSmithKline plc (UK)

  • Pfizer Inc. (US)

  • Johnson & Johnson Services, Inc. (US)

  • Dr. Reddy‚Äôs Laboratories Limited (India)

  • Lupin Pharmaceuticals, Inc. (India)

  • Aurobindo Pharma (India)

  • Zydus Cadila (India)

  • Apotex Inc. (Canada)

  • Teva Pharmaceutical Industries Ltd (Israel)¬†


Bulimia Nervosa Market Scenario


The Bulimia Nervosa Market is projected to reach USD 735.8 Million by 2030 at 6% CAGR during the forecast period 2022-2030. Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems. Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth. However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth.   


Segmentation


The bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region. Based on disorder type, the bulimia nervosa market has been divided into purging and non-purging. The bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others. Based on route of administration, the bulimia nervosa market is segmented into oral, intravenous, and others. The bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others. The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.  The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Middle East & Africa bulimia nervosa market is segmented into the Middle East and Africa.    


Key Players


Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India) are some of the key players operating in the market.


Regional Market Summary  


 Bulimia Nervosa Market Share (%), by Region, 2018


Bulimia Nervosa Market Share Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the  bulimia nervosa market owing to the rising prevalence of bulimia nervosa. According to data published by the National Institute of Mental Health (NIMH) in November 2017, 43.2% people suffering from bulimia nervosa sought treatment for their disorder in the US. Europe is expected to hold the second-largest share of the bulimia nervosa market owing to the presence of major market players such as AstraZeneca and GlaxoSmithKline plc. Asia-Pacific is expected to be the fastest-growing regional market owing to the rising awareness regarding mental disorders and high incidence rate of bulimia nervosa. The bulimia nervosa market in the Middle East & Africa is expected to hold the least share during the forecast period.  


Market for Bulimia Nervosa, by Disorder Type



  • Purging

  • Non-Purging


Market for Bulimia Nervosa, by Drug Type



  • Antidepressants

  • Antipsychotics

  • Others


Market for Bulimia Nervosa, by Route of Administration



  • Oral

  • Intravenous

  • Others


Market for Bulimia Nervosa, by End User



  • Hospitals and Clinics

  • Homecare Settings

  • Specialty Centers

  • Others


Market  for Bulimia Nervosa, by Region



  • Americas


    • North America

    • US

    • Canada

    • Latin America




  • Europe


    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Biotechnology companies

  • Research institutes

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.